Earnings Highlights
EPS Actual
-0.45
EPS Estimate
-0.50
Revenue Actual
Revenue Estimate
***
system analysis Users gain access to financial insights covering earnings releases, market volatility, and sector rotation trends across global equities. Enanta Pharmaceuticals reported a Q1 2026 net loss per share of -$0.45, surpassing the consensus estimate of -$0.4978 by approximately 9.6%. As a clinical-stage biotechnology company with no approved products, the firm did not report revenue. Shares rose 0.87% in after-hours trading following the announcement.